HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's Disease
Kennedy, Nicholas A.
Bewshea, Claire M.
Walker, Gareth J.
Perry, Mandy H.
McDonald, Timothy J.
Goodhand, James R.
RightsThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Attribution-NonCommercial-NoDerivs 3.0 United States
MetadataShow full item record
Anti-tumor necrosis factor (anti-TNF) therapies are the most widely used biologic drugs for treating immune-mediated diseases, but repeated administration can induce the formation of anti-drug antibodies. The ability to identify patients at increased risk for development of anti-drug antibodies would facilitate selection of therapy and use of preventative strategies.
CitationSazonovs A [et al]. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's Disease. Gastroenterology. 2020 Jan;158(1):189-199
NoteThis article is freely available via Open Access. Click on Publisher URL to access the full-text.
The following license files are associated with this item: